You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Recyclable Magnetic Co C Hybrid ROMP Reagents Scavengers and Ligands

    SBC: MATERIA, INC.            Topic: 300

    DESCRIPTION provided by applicant This Fast Track Small Business Technology Transfer study between Materia Inc in Pasadena CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant R GM which ends on March Preliminary results serve as a solid foundation for this Fast Track submission entitled andquot Development of Re ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Infant Screening of Early Communication Risk: The CISS, Phase II

    SBC: PAUL H BROOKES PUBLISHING CO., INC.            Topic: Y

    DESCRIPTIONprovided by applicantEffective early intervention depends on reliable screening of risk for communication impairments as soon as possibleEstablished infant communication risk factors include poor attentiongesturessocial connectednessexploratory playand speechAlthough these risk factors can be detected bymosand reliably predict later language and social disordersattempts to detect simila ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Tribosupplementation of Injured Joints

    SBC: TRIBOLOGICS, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Joint injury is a well established risk factor in the pathogenesis of post-traumatic osteoarthritis (PTOA). In particular, patients with meniscal tears are at high risk for early PTOA. Chondroprotection of the joint surface is mediated by lubricin, a large glycoprotien which forms a lubricating nanofilm on the cartilage surface and provides anti-adhesion via st ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: CETYA THERAPEUTICS, INC.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    SBC: VALA SCIENCES, INC.            Topic: NHLBI

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Diffraction From Microvolume Topaz Microprocessors

    SBC: FLUIDIGM CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): We intend to develop an improved microfluidic device that allows crystallization experiments to be interrogated directly with X-ray radiation without requiring crystals to be removed from the well. This will allow experimenters to assess the outcome of crystallization experiments on the basis of diffraction data rather than arbitrary optical judgments. Identifi ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  9. DEVELOPMENT OF STANDARDIZED MILK THISTLE PRODUCT

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (Provided by applicant): The objective of this Phase I and II fast track application is to develop a standardized milk thistle product and to assure a quality controlled and reliable source for future basic and clinical studies. Natural Pharmacia International, Inc, an established natural products laboratory, has established an excellent consortial team to establish a standardized milk ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  10. Behavioral Intervention in Autism: Practitioner Skills

    SBC: PRAXIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Autism Spectrum Disorder (ASD) is a complex neurological disorder that typically appears before the age of three and immediately and profoundly affects a young child's ability to communicate, develop language, form social relationships and respond appropriately to environmental cues. Whereas all children with developmental disabilities receive some form of fede ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government